{
    "organizations": [],
    "uuid": "5e70ffbc218aaa2dd81d353a08bf8272e6623ade",
    "author": "Charley Grant",
    "url": "https://www.wsj.com/articles/celgene-cant-cure-the-biotech-blues-1515435381",
    "ord_in_thread": 0,
    "title": "Celgene Can’t Cure the Biotech Blues",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Good news isn’t helping a key biotech bellwether turn its fortunes around. That suggests a gloomy year for the sector.\nCelgene, one of the world’s largest biotech companies, announced Monday it expects sales of about $14.6 billion and adjusted earnings of about $8.80 a share in 2018. That’s in line with analyst expectations. But Celgene—and the sector—traded lower on Monday.\nCelgene... ",
    "published": "2018-01-08T21:16:00.000+02:00",
    "crawled": "2018-01-08T21:43:04.022+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "good",
        "news",
        "helping",
        "key",
        "biotech",
        "bellwether",
        "turn",
        "fortune",
        "around",
        "suggests",
        "gloomy",
        "year",
        "sector",
        "celgene",
        "one",
        "world",
        "largest",
        "biotech",
        "company",
        "announced",
        "monday",
        "expects",
        "sale",
        "billion",
        "adjusted",
        "earnings",
        "share",
        "line",
        "analyst",
        "expectation",
        "lower",
        "monday",
        "celgene"
    ]
}